Pacylex Pharmaceuticals, Inc.

Pacylex Pharmaceuticals Presents Progress on NMT Inhibitors for Cancer at February Industry Conferences - pacylex.reportablenews.com/pr/pacylex-pha…

🧬 Michael Weickert, PhD @Weickert @Pacylex, discusses Zelenirstat, a first-in-class therapy targeting a new pathway. Phase 1 revealed unexpected efficacy. 📈 @ASCO #GI24 #Oncology Watch the [VIDEO]: allen-oncologytu.cincopa.com/watch/A4HAcLOL… 🎥 Stay updated: medicusnetworks.net/ENEWSLETTER-SU…

Happening Now: The AACR Annual Meeting! #AACR2024 LC is excited to participate in the meeting and share the latest information on the patient experience, “Cancer related fatigue and the additive effect of treatment in the context of lymphoma and CLL: An analysis of Lymphoma Coalition’s 2022 Global Patient Survey.” 📌 Poster Presentation Details: 🕒 Time: Apr. 8, 2024, 9:00 AM - 12:30 PM 📍 Session PO.SHP01.01 - Science and Health Policy To view the full abstract visit: abstractsonline.com/pp8/#!/20272/p…

Pacylex Pharmaceuticals Reports Zelenirstat Disrupts Oxidative Phosphorylation in Cancer Cells at AACR 2024 - Defines a second potential mechanism which may account for early signs of zelenirstat anti-cancer activity in the Phase 1 study pacylex.reportablenews.com/pr/pacylex-pha….

Next week AACR. Then Boston, ASCO and BIO. Excited to share news from our trials. buff.ly/4a4q8BC

Honored to be a presenting part of this great community dedicated to science for patients. Thanks for your interest in our company! buff.ly/4a4q8BC

Announcing Pacylex at AACR. Poster Title: N-myristoylation inhibitor zelenirstat: new mechanistic insights and efficacy signals from a first in human phase I study. buff.ly/4a4q8BC

Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. buff.ly/3iqLZrD

We are proud to present these distinguished journalists with the 2024 AACR June L. Biedler Prize for Cancer Journalism. Learn more: bit.ly/494ScUf @bethrites @HellenShikandah @rosafurneaux @lauramarg @nell_sci_NPR @annawerner @LeighAnnWinick

Target Oncology interviewed Dr. Randeep Sangha, our Principal Investigator for zelenirstat in our Phase 1/2 clinical study: Zelenirstat Shows Evidence of Clinical Benefit Across Advanced Cancers targetedonc.com/view/zelenirst…

Our CEO was at ASCO-GI presenting our results in patients with gastrointestinal cancers. He shared the Phase 1 clinical experience with zelenirstat, our first in class, oral, cancer medicine in Phase 2. Take a look. allen-oncologytu.cincopa.com/watch/A4HAcLOL… Best regards, Michael

We’re excited to attend the MedInvest Oncology Investor Conference this week! Our CEO, Michael Weickert will be sharing the Company's Phase 1 study results for zelenirstat, a first in class oral therapy in development for patients with hematologic and solid tumors.

Pacylex is presenting data on mechanisms by which PCLX-001 kills cancer cells and a gene expression signature that predicts that cancers most likely to respond pacylex.reportablenews.com/pr/pacylex-pha… #cancer #lymphoma #leukemia #albertacancer #Pacylex #PCLX001 #UAlberta #EACR2023 #EHA2023 #MDACC

We heard about @pacylex' exciting developments from the company's CEO, Michael Weickert #BIO2023 #BioTechNation

Pacylex Pharmaceutical's CEO Michael Weickert will discuss exciting progress on the PCLX-001 clinical development program at the 2023 BIO International Convention June 5-8, 2023, at the Boston Convention & Exhibition Center. pacylex.reportablenews.com/pr/pacylex-pha… #BIO2023 @IAmBiotech

Pacylex Pharmaceuticals to Attend 2023 BIO to share exciting progress on the PCLX-001 clinical development program. pacylex.reportablenews.com/pr/pacylex-pha… #StandUpForScience #BIO2023 #cancertherapy #leukemia #lymphoma @IAmBiotech

ASH is working to advance research & care in #hematology. On #WorldBloodCancerDay, we're proud to share our committment to #hemeonc through our dedication to improving the use of #immunotherapies 🩸🧬 Learn more: loom.ly/O6OjNy8

The Phase 2a expansion study will enroll up to 20 patients with refractory/relapsing NHL to assess the preliminary clinical activity of NMT inhibitor PCLX-001. pacylex.reportablenews.com/pr/pacylex-pha… #Phase2a #firstpatientdosed #cancer #NHL #NonHodgkinLymphoma #PCLX001